To evaluate the safety and efficacy of extended remdesivir infusion, targeting on immunocompromised individuals who had positive SARS-CoV-2 PCR despite an oral antiviral agent prescription.
Age ≥ 18 years
Receive B-cell depletion therapy or bendamustine within 6months
Laboratory confirmed SARS-CoV-2 infection
Symptoms onset within 72 hours
Prior use of any anti-SARS-CoV-2 agents within 2 weeks. Remdesivir or NMV/r initiated within 24 hours is acceptable
Life expectancy < 1 month
Previous adverse effect related to remdesivir or NMV/r
Concurrent use medicine with drug-drug interaction with NMV/r